Discounted Cash Flow (DCF) Analysis Unlevered

Strongbridge Biopharma plc (SBBP)

$2

+0.03 (+1.52%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2 | undervalue

Operating Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2
Beta 1.596
Diluted Shares Outstanding 56.11
Cost of Debt
Tax Rate 0.03
After-tax Cost of Debt 7.34%
Risk-Free Rate
Market Risk Premium
Cost of Equity 11.131
Total Debt 18.19
Total Equity 112.21
Total Capital 130.40
Debt Weighting 13.95
Equity Weighting 86.05
Wacc

Build Up Free Cash

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 5.37%-1.59%1.65%-3.71%0.03%0.35%0.35%0.35%0.35%0.35%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure ---0.33-0.07-0.01-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.60
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -69.33
Equity Value -
Shares Outstanding 56.11
Equity Value Per Share -